Autumn Brings Personnel Changes In Geneva 12/08/2011 by Catherine Saez, Intellectual Property Watch Leave a Comment The annual summer shuffle of the mission staff in Geneva has been particularly active this year for those with responsibility for intellectual property rights, with several key diplomats packing their bags, and new ones arriving.
Corporate Self-Interest And Strategic Choices: Gilead Licenses To Medicines Patent Pool 21/07/2011 by Intellectual Property Watch 3 Comments Gilead’s recently announced ARV licenses to the Medicines Patent Pool, although positive in some respects, still unreasonably limit the geographical access of key middle-income countries and restrict the sourcing of APIs and products to Indian companies, meaning that both generics companies and excluded countries will need to make strategic decisions to bypass the defects in the licenses, writes Brook Baker.
Neglected Diseases R&D Financing Proposals Shaping Up At WHO 14/07/2011 by Intellectual Property Watch Leave a Comment Global public health experts in charge of exploring ways to finance R&D on diseases endemic in developing countries last week provided a preliminary summary of assessments on proposals provided by various stakeholders. They also made recommendations to establish global mechanisms, including a binding global instrument for R&D and innovation for health.
WHO Enters Next Phase Of Global Plan To Increase Flu Vaccine Production 14/07/2011 by Catherine Saez, Intellectual Property Watch 1 Comment The World Health Organization will be entering a new phase of its global action plan for influenza vaccines, a WHO representative told reporters today. The goals of the first phase of the programme should be furthered but with more attention given to the local health and policy environment, WHO said.
Medicines Patent Pool Boosts HIV Drug Prospects With First Licence 12/07/2011 by William New, Intellectual Property Watch 4 Comments The Medicines Patent Pool and pharmaceutical company Gilead Sciences today announced a breakthrough licence agreement to allow for the production of key HIV medicines at lower cost and in an easier-to-use formulation, making them more accessible to developing countries. The agreement also opens up the use of treatments for Hepatitis B for the first time.
Non-Communicable Diseases Issue Energises Public Health Policymakers 07/07/2011 by William New, Intellectual Property Watch Leave a Comment Concern over non-communicable diseases – traditionally a more developed-country set of problems like diabetes – is energising the international public health policy community. But representatives of the public interest are still grappling with their response.
WHO Expert Group Sifts Ideas For A New Global Drug R&D Mechanism 05/07/2011 by William New, Intellectual Property Watch 1 Comment A diverse team of global experts on public health research and development will meet this week behind closed doors to analyse proposals for ways to fund R&D on diseases afflicting poor populations – and for who should coordinate such global efforts.
Amending Canada’s Access To Medicines Regime (CAMR): The New Fate Of Bill C-393 28/06/2011 by Intellectual Property Watch 4 Comments A Canadian bill to improve global access to medicines might get another shot in the new Parliament, writes Daniele Dionisio.
Plain Packaging For Tobacco Raises IPR Questions At WTO 16/06/2011 by Catherine Saez, Intellectual Property Watch 2 Comments At the last session of the World Trade Organization Trade-Related Aspects of Intellectual Property Rights (TRIPS) Council, the Dominican Republic challenged an Australian draft law requiring plain packaging for tobacco products as being incompatible with its WTO obligations, eclipsing other agenda items. The TRIPS Council also addressed other regular agenda items such as related to biodiversity and public health, according to sources.
Targets, TRIPS Flexibilities In UN HIV Meeting Declaration; Brazil’s Health Minister Hails Outcome 10/06/2011 by William New, Intellectual Property Watch Leave a Comment NEW YORK – The declaration from the United Nations High-Level Meeting on AIDS, which concluded today, set targets for responding to the disease and contained clear references to flexibilities to intellectual property law intended to assure needed medicines can be obtained affordably, according to Brazil’s health minister.